In Brief: Cordis/Biosense
This article was originally published in The Gray Sheet
Executive Summary
Cordis/Biosense: Firms enter agreement under which Miami, Florida-based Cordis gains exclusive worldwide marketing rights for electrophysiology, neuroradiology, and neuroendoscopy products based on Biosense's technology for "miniature high-resolution location detection of indwelling catheters and other medical devices," Cordis states. A system currently under development by privately held Biosense, designed to "locate in real-time and in three dimensions the precise position and orientation of catheters and other medical devices positioned within the body," is currently in clinical trials in Israel and Europe. The device could shorten procedure time from the current 4-5 hours to less than 2 hours, and "eliminate most of the fluoroscopy associated with electrophysiology mapping," the firm claims. An electrophysiology product incorporating Biosense's technology is expected to be released outside the U.S. by early 1996, Cordis says. Cordis will take a minority position in Biosense; other terms of the agreement were not disclosed...
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.